# Multi‐year and multi‐trait evaluation of hemp ( Cannabis sativa L.) genotypes using AMMI, GGE, WAASB, and MGIDI

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/ced-uncovering-sex-differences-in-thc-response-an-2026-10-30/
> **Published:** 2026-10-30T12:54:12-04:00 | **Last Modified / Clinically Audited:** 2026-10-30T12:54:12-04:00
> **Clinical Summary:** cannabis news digest: CED Clinic analysis of 3 recent cannabis policy, science, and regulatory developments with Dr. Benjamin Caplan.

---

CED Clinical Relevance #65 Verified Overview Curated multi-source overview preserving 3 verified developments.

Clinical Insight | CED Clinic
Clinical responses to smoked cannabis depend heavily on baseline consumption habits and biological sex. Occasional male consumers display heightened vulnerability to acute dysphoria and impairment at modest THC doses around 20mg to 60mg, whereas frequent consumers exhibit selective tolerance to intoxication while retaining strong self-administration behaviors. These pharmacodynamic variations underline the necessity of cautious initial titrations for naive patients. Parallel advances in nanoemulsions, PLGA hydrogels, and standardized hemp cultivation provide the mechanical tools required to move beyond variable inhalation toward predictable, sustained therapeutic delivery.

DigestCannabis NewsRegulationPublic HealthClinical Practice

AudiencePatients, clinicians, healthcare professionals, regulators, and industry researchers.
Primary TopicClinical and policy analysis: Multi‐year and multi‐trait evaluation of hemp ( Cannabi.
Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42957841/)

Table of Contents

- [Multi‐year and multi‐trait evaluation of hemp ( Cannabis sativa L.) genotypes using AMMI, GGE, WAASB, and MGIDI](#Multiyear_and_multitrait_evaluation_of_hemp_Cannabis_sativa_L_genotypes_using_AMMI_GGE_WAASB_and_MGIDI)[How to Interpret This Cannabis News & Regulatory Digest](#How_to_Interpret_This_Cannabis_News_Regulatory_Digest)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading)
- [CED Perspective Lens: Eight Viewpoints on These Updates](#CED_Perspective_Lens_Eight_Viewpoints_on_These_Updates)[Understanding How Your Body Reacts to Cannabis](#Understanding_How_Your_Body_Reacts_to_Cannabis)
- [Tailoring Titration to Sex and Prior Exposure](#Tailoring_Titration_to_Sex_and_Prior_Exposure)
- [Minimizing Acute Dysphoria and Product Instability](#Minimizing_Acute_Dysphoria_and_Product_Instability)
- [Standardizing Dosing Rules and Crop Yields](#Standardizing_Dosing_Rules_and_Crop_Yields)
- [Bridging Human Pharmacology and Materials Science](#Bridging_Human_Pharmacology_and_Materials_Science)
- [Evaluating Preliminary Signals and Lab Models](#Evaluating_Preliminary_Signals_and_Lab_Models)
- [Guiding Family Members on Safe Consumption](#Guiding_Family_Members_on_Safe_Consumption)
- [Combining Personalized Care with Bioengineering](#Combining_Personalized_Care_with_Bioengineering)
- [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related)

# Multi‐year and multi‐trait evaluation of hemp ( Cannabis sativa L.) genotypes using AMMI, GGE, WAASB, and MGIDI

A structured CED Clinic overview of 3 key developments in cannabis regulation, market milestones, and scientific research.

What This Study Teaches Us
In a double-blind crossover trial of 44 healthy adults (22 females), occasional-use males reported significantly higher sedation, dysphoric arousal, and bad effects from smoked THC (4% and 10% strengths) compared to females or frequent users. Meanwhile, advanced CBD delivery research highlights that polymeric biomaterials and 3D-bioprinted hydrogels overcome low aqueous bioavailability by enabling controlled, stimuli-responsive release. Agricultural multi-year modeling using AMMI and GGE indices identifies specific hemp genotypes capable of maintaining stable cannabinoid profiles across varying environmental conditions.

Why This Matters
Sex and consumption frequency interact directly to dictate acute psychiatric and sedative reactions to smoked cannabis, requiring personalized dosing strategies. Concurrently, precise biomaterial delivery systems and standardized agronomic cultivation ensure reliable cannabinoid concentrations for clinical applications.

Study SnapshotPost TypeCannabis News & Regulatory Digest using canonical CED layoutItems Reviewed3 verified updatesPrimary DatesOctober 30, 2026Related Reading3 verified live CED Clinic internal linksUpdate 1Sex- and frequency-dependent acute pharmacokinetic (Lake et al., Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology) [DOI: 10.1038/s41386-026-02571-3 | PMID: 42957841]Update 2Advanced cannabidiol delivery platforms: smart (Shabbir et al., Journal of drug targeting) [DOI: 10.1080/1061186X.2026.2755447 | PMID: 42956359]Update 3Multi‐year and multi‐trait evaluation of (Yazıcı et al., Crop Science) [DOI: 10.1002/csc2.70391]

Clinical Bottom Line
This clinical and regulatory overview preserves key signals across 3 updates without overstatement, offering grounded guidance for patients and practitioners.

Context Across These 3 Updates

This curated cannabis news & regulatory digest brings together 3 key developments across policy movements, regulatory milestones, and public health communications. Reviewing these distinct updates side by side clarifies emerging patterns while preserving the specific clinical context of each report.

Examining these developments concurrently helps clinicians, patients, and families trace the broader trajectory of the field while grounding practical decisions in verified primary data.

Update 1: Sex- and frequency-dependent acute pharmacokinetic and pharmacodynamic effects

**Title & Source:** [Sex- and frequency-dependent acute pharmacokinetic and pharmacodynamic effects of smoked cannabis: a randomized controlled trial.](https://pubmed.ncbi.nlm.nih.gov/42957841/) (*Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*, 2026Oct29)

**Lead Authors & Identifiers:** Stephanie Lake, Elisa Pabon, Samantha L Baglot, Alisha Eversole et al.. | **Primary Record:** DOI: 10.1038/s41386-026-02571-3 | PMID: 42957841 Content lane: **Clinical Evidence Update**.

**Investigational Focus:** This randomized, double-blind, placebo-controlled crossover study examined 44 healthy adults (22 females) categorized by cannabis use frequency (>4 vs

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).